Spitalul Judetean De Urgenta Sfantul Ioan Cel Nou Suceava
- Address
- lock Available on a paid plan
Spitalul Judetean De Urgenta Sfantul Ioan Cel Nou Suceava - Multi-Specialty Clinical Research Center
Spitalul Judetean De Urgenta Sfantul Ioan Cel Nou Suceava is an active clinical research center engaged in diverse therapeutic investigations spanning metabolic, autoimmune, infectious, and oncological diseases. The center demonstrates comprehensive capability in conducting Phase 3 clinical trials across multiple medical specialties, contributing to the advancement of novel treatment approaches for complex chronic conditions.
- Chronic Kidney Disease and Hypertension - investigating combination therapies for cardiovascular and renal protection
- Diabetes Management - evaluating novel insulin formulations including once-weekly insulin icodec for Type 1 Diabetes
- Autoimmune and Inflammatory Disorders - studying biologic therapies for Psoriatic Arthritis and Chronic Obstructive Pulmonary Disease
- Oncology and Infectious Diseases - conducting trials in metastatic colorectal cancer with microsatellite instability and chronic Hepatitis B
The center's research portfolio reflects expertise in evaluating immunotherapy combinations, targeted biological agents, and novel therapeutic regimens aimed at achieving functional cure or disease modification. With particular strength in metabolic disorders and chronic disease management, the facility supports investigations ranging from traditional pharmacological interventions to cutting-edge immunomodulatory approaches, demonstrating commitment to improving patient outcomes across diverse disease states.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 7 therapeutic areas and 15 of 26 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AstraZeneca AB1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Atea Pharmaceuticals Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Spitalul Judetean De Urgenta Sfantul Ioan Cel Nou Suceava
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Comparison of Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 with Insulin Aspart in Adults with Type 1 Diabetes | Novo Nordisk A/S | Phase III | Not Recruiting | Aug 2025 | — |
IMP list
lock Showing 1 of 26 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apixaban | 1 | Unknown | 2022-11-24 | 2022-11-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.